Presentations

• December 8, 2017
  

  Characterizing Disease Progression for Parkinson’s Disease to implement efficient trial designs

• December 8, 2017
  

  Model-Informed Biomarker Qualification: Alzheimer and Parkinson Disease Imaging Biomarkers

• November 15, 2017
  

  Using Data to Reimagine Clinical Trials

• November 6, 2017 - November 7, 2017
  

  Proceedings from Huntington’s Disease Regulatory Science Consortium (HD-RSC) Kick-Off Meeting, Nov. 6-7, 2017

  On November 6 and 7, 2017, in Silver Spring, MD, Critical Path Institute and CHDI Foundation welcomed participants from the pharmaceutical industry, academia, regulatory agencies, and advocacy groups to a kick-off meeting for the Huntington’s Disease Regulatory Science Consortium (HD-RSC). The meeting objectives were to solicit input from stakeholders on HD-RSC plans and deliverables, and...
• November 4, 2017
  

  Allowing Respondents to Skip Items During Electronic Collection of Patient-Reported Outcome (PRO) Data: Does It Matter?

  O’Donohoe P, Eremenco S, Coons SJ, Crescioni M, Arnera V. Allowing Respondents to Skip Items During Electronic Collection of Patient-Reported Outcome (PRO) Data: Does It Matter? International Society for Pharmacoeconomics and Outcomes Research 20th Annual European Congress; 2017 Nov 4; Glasgow, Scotland.